Positions

Overview

  • Introduction:
    Graduate of Duke University undergraduate and Chapel Hill Medical School. Completed internship/residency at UAB followed by fellowship at UAB. Currently Professor of Medicine with a focused interest in education, clinical investigation in head and neck cancer and breast cancer, and quality metrics for patient care.

    Clinical Interests:

    Clinical investigation in head and neck cancer and breast cancer, and quality metrics for patient care.

    Research:

    Head and Neck Cancer, Breast Cancer, GU Cancer, and Sarcoma.
  • Research Overview

  • Head and Neck Cancer
    Breast Cancer
    GU cancer
    Sarcoma
  • Principal Investigator On

  • A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases  awarded by University of North Carolina at Chapel Hill
  • Private Grant  awarded by VIVENTIA BIO, INC.
  • Private Grant  awarded by EXELIXIS, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by ONCOLYTICS BIOTECH
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by ONCOTHYREON, INC.
  • Private Grant  awarded by ONCOTHYREON, INC.
  • Private Grant  awarded by ONCONOVA THERAPEUTICS
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by DYNAVAX TECHNOLOGIES CORPORATION
  • Private Grant  awarded by ALTOR BIOSCIENCE CORPORATION
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by MERCK & COMPANY, INC. ^
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by ACERTA PHARMA B.V.
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by IOVANCE BIOTHERAPEUTICS INC.
  • Private Grant  awarded by Bayer HealthCare
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by ADURO BIOTECH, INC.
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by HOOKIPA BIOTECH
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by REPLIMUNE INC.
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by ELIOS THERAPEUTICS
  • Private Grant  awarded by IMMUTEP LTD
  • Private Grant  awarded by IDERA PHARMACEUTICALS, INC.
  • UAB 1018/TBCRC 011; Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)), Metastatic Breast Cancer Patients: A Phase II Feasibility Study  awarded by SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
  • UAB 1428 – A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer (HOG Trial)  awarded by HOOSIER CANCER RESEARCH NETWORK
  • Investigator On

  • A Prospective Analysis of Surgery in Patients Presenting with Stage IV Breast Cancer - TBCRC 013 / UAB 0953  awarded by Johns Hopkins University
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • Biomarkers for Detection of Renal Cell Carcinoma  awarded by American Cancer Society, Inc.
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Imaging Guided Surgery using Fluorescently Labeled Cetuximab  awarded by National Cancer Institute/NIH/DHHS
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • Phase 1, Open-Label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer during Surgical Procedures  awarded by Stanford University
  • Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures  awarded by Stanford University
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by PNP THERAPEUTICS, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by OBI PHARMA, INC.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by DYNASPLINTT SYSTEM, INC.
  • Private Grant  awarded by WYETH PHARMACEUTICALS, INC.
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by MERRIMACK PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by NOVADAQ TECHNOLOGIES, INC.
  • Private Grant  awarded by SYNTA PHARMACEUTICALS
  • Private Grant  awarded by MERRIMACK PHARMACEUTICALS, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by AVEO PHARMACEUTICALS, INC
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by Novartis Pharma AG
  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC.
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by SELEXYS
  • Private Grant  awarded by CYCLACEL LTD
  • Private Grant  awarded by LICOR, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by SUCAMPO PHARMACEUTICALS
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by NOVADAQ TECHNOLOGIES, INC.
  • Private Grant  awarded by REXAHN PHARMACEUTICALS, INC.
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by REXAHN PHARMACEUTICALS, INC.
  • Private Grant  awarded by CLOVIS ONCOLOGY
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by CLOVIS ONCOLOGY
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by IMAGINAB^
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC.
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by TACTILE MEDICAL
  • Private Grant  awarded by MUREVA PHOTOTHERAPY INC
  • Private Grant  awarded by JOUNCE THERAPEUTICS, INC
  • Private Grant  awarded by STRATA ONCOLOGY
  • Reduction of Tumor-Positive Margins in Oncology Surgery  awarded by National Cancer Institute/NIH/DHHS
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • Southwest Oncology Group Clinical Trials Initiative Purchase Service Agreement  awarded by SOUTHWEST ONCOLOGY GROUP
  • Southwest Oncology Group Purchase Service Agreement  awarded by SOUTHWEST ONCOLOGY GROUP
  • TBCRC 026/UAB 1367: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer (ML28190)  awarded by Johns Hopkins University
  • TBCRC 036 (UAB 1366): Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab + Pertuzumab, or Combination Trastuzumab + Lapatinib  awarded by Lineberger Comprehensive Care Center
  • TBCRC 042 UAB 1905: A Randomized, Phase II, Window-of-Opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions  awarded by Johns Hopkins University
  • TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker  awarded by Johns Hopkins University
  • UAB 1018/TBCRC 011; Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-), Metastatic Breast Cancer Patients: A Phase II Feasibility Study  awarded by Johns Hopkins University
  • UAB 1019/TBCRC 015: Investigation of Genetic Determinants of Capecitabine Toxicity  awarded by Johns Hopkins University
  • UAB 1033/TBCRC 018: A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201) in Combination with Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis  awarded by Johns Hopkins University
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE
  • UAB 1326: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-Amplified but HER2 Mutant Breast Cancer  awarded by Washington University
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • XUAB 2167 - A Phase II Circulating Tumor DNA Enriched, Gnomically Directed Post-Neoadjuvant Trial for Patients with Residual Triple Negative Breast Cancer (PERSEVERE): HCRN BRE18-334  awarded by HOOSIER CANCER RESEARCH NETWORK
  • [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Women with Newly Diagnosed Metastatic Breast Cancer (R20-146)  awarded by ECOG-ACRIN CANCER RESEARCH GROUP
  • Education And Training

  • UAB Hospital, Internship
  • UAB Hospital, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, University of North Carolina System : Chapel Hill 1987
  • Full Name

  • Lisle Nabell